Fig 5 -
<p>Funnel plots of survival (A), EFSR (B), pathological responses (C), and safety summary (D).</p>
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1852026445548748800 |
|---|---|
| author | Hai Huang (140371) |
| author2 | Lianyun Li (3435095) Ling Tong (632992) Houfu Luo (19727416) Huijing Luo (19727419) Qimin Zhang (17692601) |
| author2_role | author author author author author |
| author_facet | Hai Huang (140371) Lianyun Li (3435095) Ling Tong (632992) Houfu Luo (19727416) Huijing Luo (19727419) Qimin Zhang (17692601) |
| author_role | author |
| dc.creator.none.fl_str_mv | Hai Huang (140371) Lianyun Li (3435095) Ling Tong (632992) Houfu Luo (19727416) Huijing Luo (19727419) Qimin Zhang (17692601) |
| dc.date.none.fl_str_mv | 2024-09-23T17:30:43Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pone.0310808.g005 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Fig_5_-/27090514 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biochemistry Medicine Cell Biology Pharmacology Biotechnology Developmental Biology Cancer treatment discontinuations due shown promising results 6 &# 8211 12 &# 8211 major pathological response significantly improve survival prolonged survival times ppi group experienced 5 aes must rr ]: 5 77 ]), event xlink "> pd hr ]: 0 xlink "> 5 aes pathological responses serious aes free survival substantial evidence still lacking seen across scale studies risk ratio resectable nsclc resectable non rcts ), r0 resections primary endpoint ppi cohort perioperative setting perioperative pd nsclc ). l1 inhibitors increased incidence hazard ratio analysis based analysis aims adverse events adjuvant therapies 82 ]). 57 ]), 48 months |
| dc.title.none.fl_str_mv | Fig 5 - |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>Funnel plots of survival (A), EFSR (B), pathological responses (C), and safety summary (D).</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_21cda2dbdcd3ab8dc0200e30e037ea3f |
| identifier_str_mv | 10.1371/journal.pone.0310808.g005 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/27090514 |
| publishDate | 2024 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Fig 5 - Hai Huang (140371)Lianyun Li (3435095)Ling Tong (632992)Houfu Luo (19727416)Huijing Luo (19727419)Qimin Zhang (17692601)BiochemistryMedicineCell BiologyPharmacologyBiotechnologyDevelopmental BiologyCancertreatment discontinuations dueshown promising results6 &# 821112 &# 8211major pathological responsesignificantly improve survivalprolonged survival timesppi group experienced5 aes mustrr ]: 577 ]), eventxlink "> pdhr ]: 0xlink ">5 aespathological responsesserious aesfree survivalsubstantial evidencestill lackingseen acrossscale studiesrisk ratioresectable nsclcresectable nonrcts ),r0 resectionsprimary endpointppi cohortperioperative settingperioperative pdnsclc ).l1 inhibitorsincreased incidencehazard ratioanalysis basedanalysis aimsadverse eventsadjuvant therapies82 ]).57 ]),48 months<p>Funnel plots of survival (A), EFSR (B), pathological responses (C), and safety summary (D).</p>2024-09-23T17:30:43ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1371/journal.pone.0310808.g005https://figshare.com/articles/figure/Fig_5_-/27090514CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/270905142024-09-23T17:30:43Z |
| spellingShingle | Fig 5 - Hai Huang (140371) Biochemistry Medicine Cell Biology Pharmacology Biotechnology Developmental Biology Cancer treatment discontinuations due shown promising results 6 &# 8211 12 &# 8211 major pathological response significantly improve survival prolonged survival times ppi group experienced 5 aes must rr ]: 5 77 ]), event xlink "> pd hr ]: 0 xlink "> 5 aes pathological responses serious aes free survival substantial evidence still lacking seen across scale studies risk ratio resectable nsclc resectable non rcts ), r0 resections primary endpoint ppi cohort perioperative setting perioperative pd nsclc ). l1 inhibitors increased incidence hazard ratio analysis based analysis aims adverse events adjuvant therapies 82 ]). 57 ]), 48 months |
| status_str | publishedVersion |
| title | Fig 5 - |
| title_full | Fig 5 - |
| title_fullStr | Fig 5 - |
| title_full_unstemmed | Fig 5 - |
| title_short | Fig 5 - |
| title_sort | Fig 5 - |
| topic | Biochemistry Medicine Cell Biology Pharmacology Biotechnology Developmental Biology Cancer treatment discontinuations due shown promising results 6 &# 8211 12 &# 8211 major pathological response significantly improve survival prolonged survival times ppi group experienced 5 aes must rr ]: 5 77 ]), event xlink "> pd hr ]: 0 xlink "> 5 aes pathological responses serious aes free survival substantial evidence still lacking seen across scale studies risk ratio resectable nsclc resectable non rcts ), r0 resections primary endpoint ppi cohort perioperative setting perioperative pd nsclc ). l1 inhibitors increased incidence hazard ratio analysis based analysis aims adverse events adjuvant therapies 82 ]). 57 ]), 48 months |